<DOC>
	<DOC>NCT00329264</DOC>
	<brief_summary>The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Safety &amp; Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Patient has a documented clinical diagnosis of Generalized Anxiety Disorder. Be able to understand and comply with the requirements of the study. Able to understand and provide written informed consent Patients (female) must not be pregnant or lactating Current or past diagnosis of stroke or transient ischemic attack (TIA).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>GAD</keyword>
	<keyword>anxiety</keyword>
</DOC>